Back to Directory
Anastasis Biotec
Greater London
Founded 2016
Preclinical inhibitors of Notch and Mastermind cancer signalling pathways
Anastasis Biotec is a preclinical biotechnology company developing targeted inhibitors of cancer signalling pathways, with a focus on the Notch pathway and its transcriptional co-activator Mastermind. These pathways help drive tumour growth and the survival of cancer stem cells. The company is developing peptide-based inhibitor conjugates intended for a precision medicine approach, in which patients would be selected for treatment according to the driver mutations identified in their tumour biopsies.